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Summary.-In order to determine the mechanisms of relapse following response to
endocrine therapy, we have measured the oestrogen receptor (RE) content of biopsies
of breast cancer in patients receiving various types of endocrine treatment.
RE content fell in responding (means of 260 2 to 12 fmol/mg protein) and in non-
responding (means of 155.1 to 31 8 fmol/mg protein) patients who had measurable
receptor at the start of treatment. Some of these patients, and a further group of
responders to endocrine therapy, were monitored until relapse. Tumour biopsies at
the time of relapse showed that 10/14 tumour samples contained significant RE
(mean of 86-7 fmol/mg protein; range <10-271 fmol/mg protein) after successful
endocrine therapy.
No relationship could be found between RE content and plasma gonadotrophin or
steroid-hormone concentration, but the fall in RE content correlated with reduced
numbers of tumour cells in the biopsy.
These results indicate that relapse following successful endocrine therapy in
breast cancer does not appear to be due to the emergence of RE-negative tumour
cells. The fall in RE content during response to endocrine therapy may be due
to reduced tumour-cell content of the biopsy.
IT IS WELL established that the presence
of an oestrogen receptor (RE) in a breast
cancer is almost obligatory for response to
endocrine therapy (McGuire et al., 1975).
Patients who respond to therapy all
eventually relapse, however, but the
reason for relapse is not clear.
In an attempt to determine the mech-
anism of regression and relapse some
studies have been carried out in which
changes of receptor content of regressing
tumours have been measured. These
studies indicate that the receptor content
of regressing tumours fall in both rodent
mammary tumours (Arafah et al., 1980;
Cho-Chung et al., 1978; Bodwin et al.,
1978) and human breast carcinomas
(Allegra et al., 1980; Namer et al., 1980).
It is still not clear, however, whether
relapse following regression is due to
regrowth of a hormone-independent popu-
lation. For this reason we have carried out
sequential biopsies of accessible skin
metastases in patients with breast cancer,
and have determined their RE content
before and during therapy, and at the
time of relapse.
PATIENTS AND METHODS
Patients. Twenty-six patients (ages 34-
94; mean age 67) with skin metastases, exten-
sive local disease or local recurrent breast
carcinoma had skin biopsies performed
before receiving endocrine therapy, and 2-3
months later, while receiving endocrine
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therapy. In addition, a group of 13 patients
who had relapsed following a previous res-
ponse to endocrine therapy, had skin
biopsies performed. Biopsies taken at relapse
were obtained when the treatment was
stopped (3 patients) or 2-6 weeks after
therapy was discontinued in the remaining
patients. Ten of these patients then received
further endocrine therapy.
About 0-5 g tissue was removed under
lignocaine local anaesthesia and 0 4 g frozen
in liquid N2 and stored for subsequent RE
and progesterone receptor (RP) estimations.
The remaining 0-1 g was examined histolo-
gically after fixation in the standard fashion.
Histology.-Histological examination was
carried out on 50 skin nodules from 25
patients, where at least 2 skin nodule biopsies
(i.e. pre- and on treatment) were available.
As the cellularity varied from patient to
patient and, of course, between the pairs of
samples from the same patient, a quantitative
scale was devised: +, small number of single
cells scattered in the stroma; +++, con-
fluent sheets of malignant cells occupying
most of section. Anything between these two
extremes was scored as + +. All sections were
routinely stained with haematoxylin and
eosin. Some sections were additionally stained
for epithelial membrane antigen (EMA),
(Sloane & Ormerod, 1981) with the indirect
immunoperoxidase method when identifica-
tion of malignant cells was uncertain. The
histological evaluation was completed with-
out any knowledge of the tissue RE
content.
Serum hormone assays.-Serum samples
were taken at the same time as the biopsies.
Oestradiol, testosterone, follicle-stimulating
hormone (FSH) and luteinizing hormone
(LH) were measured by radioimmunoassay,
using reagents provided by the WHO Match-
ed Reagents scheme and according to WHO
recommended procedures (WHO Method
Manual, 1981). Sex-hormone-binding-globulin
(SHBG) was measured by the 2-tier column
method ofJqbal & Johnson (1977).
Hormone-receptor assays.-Receptor assays
were performed using the dextran-coated-
charcoal method to separate "bound" from
"free" hormone (McGuire et al., 1975).
Binding data were analysed by the method of
Scatchard (1949). Oestrogen and progesterone
receptor levels are expressed as fmol/mg of
cytosol protein and intra-assay variation was
10%. The interassay variation was 15%. A
concentration ofreceptor > 10 fmol/mg cyto-
sol protein is regarded as positive.
Endocrine therapy.-Eight patients were
treated with tamoxifen (T), 7 with amino-
glutethimide (A) (Smith et al., 1978) and 3
with Danazol (D) (Coombes et al., 1980) and 5
with a combination of all 3 (TAD). One
patient was treated with premarin, one by
withdrawal of premarin, and one by oophor-
ectomy.
In the group of 13 patients who had skin
biopsies following relapse after endocrine
therapy, 4 had been receiving tamoxifen,
5 aminoglutethimide, 2 premarin and 2
oophorectomy. One patient received the TAD
combination. Endocrine therapy had been
stopped 2-6 weeks before the skin biopsyin 11
cases, and 2 patients were still receiving
therapy. One patient who had relapsed after
response to tamoxifen responded to further
treatment with aminoglutethimide, and had
a further skin biopsy when she relapsed on
this therapy.
Response criteria.-Response was assessed
according to UICC criteria (Hayward et at.,
1977) with clinical measurement and photo-
graphy ofthe skin lesions, and by appropriate
investigations to determine response, or non-
response at other sites of disease.
(i) Complete response (CR) was defined as
disappearance of all clinical and radio-
logical disease for at least one month.
(ii) Partial response (PR) was defined as
>50% reduction in the product of the
2 largest perpendicular diameters of any
measurable lesion, in the absence of any
new lesions developing elsewhere, or of
further progression of known lesions, for
at least a month.
RESULTS
Changes in receptor content of skin nodules
during therapy (Tables I and II)
Skin biopsies were obtained before and
during treatment in 26 patients, 12 of
whom responded to endocrine therapy
(Table I) whilst 14 failed to respond
(Table II). RE was 3 10 fmol/mg cytosol
protein in 9/12 (75%) responders and 9/14
(64%) non-responders. Two out of 3 of
the responders without detectable RE had
received prior tamoxifen. RE content fell
in 8/9 responding patients with measurable
81R. E. TAYLOR ET AL.
TABLE I.-Receptor content of sequential biopsies in patients responding to endocrine
therapy
Pre-treatment Biopsy during
biopsy treatment
RE Pg.R. RE RP
Patienit Age
No. (yr) Therapy*
1 60 D
2 71 T
3 72 TAD
4 54 A
5 80 TAD
6 94 T
7 71 T
8 77 T
9 72 A
10 72 A
11 70 P with-
drawal
12 54 P
Means
Number showing fall
Number showing rise
(fmol/mg cytosol protein) Previous therapy
310 NQ < 10 < 10 T (stopped 4 weeks prior to D)
<10 <10 <10
541 125 < 10 < 10
<10 < 10 < 10 <10 T (stopped 4 weeks prior to A)
162 < 10 < 10 < 10 P (stopped 3 weeks prior to TAD)
737 380 < 10 < 10
31 < 10 < 10 < 10
1186 62 < 10 10 NQ
< 10 <10 < 10 < 10 T (stopped 4 weeks prior to A)
19 < 10 22 < 10 D (stopped 3 weeks prior to A)
271 < 10 <10 < 10 P (stopped 3 weeks prior to first
biopsy)
150 <10 < 10 < 10 A (stopped 16 weeks prior to P)
260-2t 60-2t 12t 5a4t
8 2
0 0
* T-Tamoxifen; A-Aminoglutethimide; D-Danazol; P-Premarin; RE-Oestrogen receptor;
RP-Progesterone receptor; NQ-Non quantifiable;
t < 10 taken as 6fmol/mg protein and 3 10 taken as 10 fmol/mg protein in calculation of means.
TABLE II.-Receptor content ofsequential biopsies inpatients not responding to endocrine
therapy
Pre-treatment
biopsy
AR P
RE RP
Biopsy during
treatment
RE RP
Patient Age
no. (yr) Therapy
1 67 T
2 76 T
3 34 Ooph.
4 71 TAD
5 74 T
6 72 D
7 72 TAD
8 79 TAD
9 44 A
10 61 D
11 54 A
12 56 A
13 83 T
14 52 A
Mean
Number showing fall
Number showing rise
( m s p
(fmol/mg cytosol protein)
133
410
24
800
<10
18
<10
247
91
<10
<10
<10
376
48
155.1
<10
<10
<10
<10
<10
<10
<10
<10
97
<10
14-2
<10
<10
19
26
<10
19
<10
<10
141
<10
<10
<10
195
<10
31-8
6
6
Previous therapy
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
< 10 T (stopped 4 weeks before 1st biopsy)
37
<10 T (stopped 4 weeks before 1st biopsy)
7.5
1
0
receptor. The receptor value fell from a
mean of 260-2 fmol/mg (range < 10-1186
to 12 fmol/mg (range < 10-22) cytosol
protein.
In the non-responders, 6/9 patients with
measurable RE showed a fall in concen-
tration, and the RE value fell from a mean
of 155-1 fmol/mg (range < 10 to 800
fmol/mg) to 31-8 fmol/mg (range < 10-195
cytosol protein.
Tamoxifen is known to occupy receptor
sites, and can therefore lead to negative
results. Of those patients who had not
received tamoxifen, 3/4 responders and
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TABLE III.-Receptor content of skin metastases from patients who have relapsed after
a previous response to endocrine therapy
Receptor
content of
recurrent tumour
.
RE
<10
<10
23
162
<10
10
271
150
48
76
167
106
102
84
RP
<10
<10
<10
<10
<10
<10
<10
<10
Subsequent
endocrine
therapy
D
A
D
TAD
A
P. withdrawal
P
A
T
T
- Norethisterone
acetate
* Relapse after 2nd course of endocrine therapy.
1/4 non-responders showed a fall in RE
Prior tamoxifen therapy appeared to give
rise to negative results for up to 4 weeks
after therapy was stopped. However, this
did not appear to prevent patients from
responding a second time, since 2 patients
with undetectable RE following tamoxifen
both responded to subsequent endocrine
therapy started shortly after the biopsy
was taken (patients 4 and 9, Table I).
Receptor content ofrecurrent skin metastases
after response to endocrine therapy (Table
III)
Skin biopsies were obtained from 13
patients when they relapsed afterrespond-
ing to a variety of endocrine agents, with
one patient being studied on 2 separate
occasions. Six of these patients have been
included in the responders, and 1 in the
non-responders mentioned above. On re-
lapse, 10/14 patients' skin metastases
contained measurable RE. One patient,
who had been receiving tamoxifen, and
whose skin biopsy was RE- at relapse,
responded to further therapy with amino-
glutethimide. When she relapsed on this
treatment, a repeat skin biopsy was RE+
(patient 12; Table III).
None of the regrowing tumour samples
contained measurable progesterone
receptor (RP).
Histology
Cellularity of skin nodules, obtained
from previously untreated patients, ap-
peared to correlate with RE content (Fig.)
All 5 samples graded as + and + + con-
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FIGURE.-Pre-treatment values for oestrogen
receptor (RE) from biopsies from skin
metastases, related to the tumour cellu-
larity (graded as +, + + or + + +; see
text for definitions). No patient had
received tamoxifen before biopsy,
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
Age
(yr)
60
54
80
72
56
70
54
52
47
65
66
59
82
Previous
therapy
T
T
A
p
T
Ooph
p
A
T
Ooph
A
A
TAD
A
Outcome
PR
PR
PD
PD
PR
PR
PR
PD
PD
Not assessed
NC
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TABLE IV.-Means + s.e. of Testosterone, Luteinizing hormone (LH), Follicle-stimulating
hormone (FSH), Oestradiol and Sex hormone binding globulin (SHBG) in responding
and non-responding patients. Serum samples taken at times of skin biopsies
Responders (n= 12)
Pre-treatment Post-treatment
Testosterone (nmol/l) 1 85+ 0-31 1-91 + 0-76
LH (u/l) 24-67+ 1-56 20-50+ 4-69
FSH (u/i) 45-67+ 5-97 32-33+ 6-01
Oestradiol (pmol/1) 100-83+ 10-44 115-83+ 27-66
SHGB (nmol DHT bound/i) 92-00+ 6-95 100-83+ 18-58
tained <50 fmol/mg cytosol protein, in
contrast to the more cellular samples.
Concerning the changes of cellularity
during therapy, irrespective of type of
endocrine treatment, 8/12 responders
showed a decrease whereas of 3/10 non-
responders showed an increase, 4 showed
unchanged cellularity, and 3 showed
a decrease.
Hormone estimations
Mean values, and standard errors of the
means for oestradiol, testosterone, follicle
stimulating hormone (FSH), luteinizing
hormone (LH) and sex hormone binding
globulin (SHBG) taken at the same times
as the biopsies from the 26 patients in
Tables I and II are shown in Table IV.
There was no significantdifferencebetween
the pre- and post-treatment values for any
of these hormones, and no correlation
between any individual hormone con-
centration and RE content.
DISCUSSION
Our results indicate that the tumour RE
content is often lowered by successful
endocrine therapy, but rises when the
tumours regrow. The initial fall in RE
content confirms the findings of other
investigators (Allegra et al., 1980, Kiang
& Kennedy, 1977; Webster et al., 1978).
These changes in RE content appear to
parallel the tumour cellularity of the
biopsy material; therefore our observed
fall in RE content may be related to the
tumour-cell content of the specimen. The
fall in RE content did not correlate with
Non-responders (n= 14)
A_
Pre-treatment Post-treatment
2-14+ 0-53 2-46+ 0-62
31-00+ 9-87 34-71+ 8-99
41-14+ 8-83 51-00+ 9-79
110-71+11-27 109-29+ 19-28
72-29+ 10-83 66-43+ 8-87
changes in serum oestradiol or any other
hormone measured, indicating that
changes in peripheral hormone concentra-
tion induced by endocrine therapy are not
the cause of changes in RE.
Ourfinding that 10/14regrowingtumour
samples had significant RE indicates that
relapse following regression is not usually
due to regrowth of a residual RE-
population of tumour cells. We are not
certain that all these tumours were RE+
at the start of treatment, but it is widely
accepted that only 4-6% of RE- tumours
respond to therapy (McGuire et al., 1978)
so these tumours were likely to have been
initially RE+.
An alternative explanation is that
endocrine therapy, for example amino-
glutethimide, is no longer capable of sup-
pressing endogenous hormone synthesis,
thus allowing endocrine-sensitive tumour
cells to regrow. Studies at this institute,
however, have shown that patients who
respond to aminoglutethimide show ade-
quate steroid suppression, even at relapse
(Coombes et al., 1981).
Many of the patients in the study were
receiving tamoxifen, or a combination.
Tamoxifen is known to bind RE, and
translocate it into the nucleus (Sutherland
& Murphy, 1980) and this may explain
why many of these patients became RE-
on therapy. Tamoxifen is known to have
a long half-life, which has been calculated
as 5-3 days (Wilkinson et al., 1980)
accounting for the prolonged RE negati-
vity of the tumours biopsied 2-4 weeks
after stopping tamoxifen. However, some
of the patients not receiving tamoxifen
also showed a marked fall in RE.
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Since patients often relapse with RE+
tumours, the biochemical changes that
have occurred to enable these tumours to
regrow in an unfavourable endocrine
environment are not clear. A better under-
standing of these mechanisms could have
therapeutic implications for maintenance
ofendocrine remission.
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